大行評級|摩根大通:上調百濟神州目標價至311港元 去年第四季業績表現向好
摩根大通發表報告指,近日與百濟神州管理層交流以及參與業績電話會議後,更確信其腫瘤學業務正處於快速上升軌道。去年第四季業績表現向好,收入按年增長約35%,主要來自於澤布替尼銷售勢頭強勁,以及產品管線研發進度迅速的帶動。
該行目前預測,若2025年公司研發管線多個項目更新研究進展,可降低臨牀風險及提升價值,將動股價上升,預計市場普遍預期將向上修正。摩通認爲百濟神州正處於一個關鍵轉折點,預測今年可錄得美國通用會計原準則下的經營利潤,除現有研發管線外,已獲批產品亦可提供估值支持,給予“增持”評級,目標價從234港元上調至311港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.